BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21701389)

  • 1. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.
    Ye X; Liu H; Wu C; Qin Y; Zang J; Gao Q; Zhang X; He J
    Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):794-800. PubMed ID: 21701389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
    Zhou B; Huang Y; Li H; Sun W; Liu J
    Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.
    Hussain S; Siddiqui AN; Habib A; Hussain MS; Najmi AK
    Rheumatol Int; 2018 Nov; 38(11):1999-2014. PubMed ID: 30159775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis.
    Islam MM; Poly TN; Walther BA; Dubey NK; Anggraini Ningrum DN; Shabbir SA; Jack Li YC
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1395-1405. PubMed ID: 30028775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
    Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
    J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
    Chiu HF; Huang YW; Chang CC; Yang CY
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
    Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
    Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
    Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors and fracture risk. The HUNT study, Norway.
    Hoff M; Skovlund E; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Forsmo S; Abrahamsen B; Schei B
    Osteoporos Int; 2020 Jan; 31(1):109-118. PubMed ID: 31741023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
    Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
    BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.
    Eom CS; Park SM; Myung SK; Yun JM; Ahn JS
    Ann Fam Med; 2011; 9(3):257-67. PubMed ID: 21555754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
    Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
    Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
    Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
    Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
    Kaye JA; Jick H
    Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
    Corley DA; Kubo A; Zhao W; Quesenberry C
    Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
    Reyes C; Formiga F; Coderch M; Hoyo J; Ferriz G; Casanovas J; Monteserín R; Brotons C; Rojas M; Moral I
    Bone; 2013 Feb; 52(2):557-61. PubMed ID: 23023097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.